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Background: We aimed to investigate the efficacy of computer-aided detection (CAD) for MRI in the assessment
of tumor extent, lymph node status, and multifocality in invasive breast cancers in comparison with other breast
imaging modalities.
Methods: Two radiologists measured the maximum tumor size, as well as, analyzed lymph node status and
multifocality in 86 patients with invasive breast cancers using mammography, ultrasound, CT, MRI with and
without CAD, and 18-fludeoxyglucose positron emission tomography (FDG-PET). The assessed data were compared
with pathology.
Results: For tumor extent, there were no significant differences between pathological size and measured size using
mammography, ultrasound, CT, or MRI with and without CAD (P > 0.05). For evaluation of lymph node status,
ultrasound had the best kappa coefficients (0.522) for agreement between imaging and pathology, and diagnostic
performance with 92.1% specificity and 90.0% positive predictive value. For multifocality, MRI with CAD had the
highest area under the receiver operating characteristic curve (AUC = 0.888).
Conclusions: CAD for MRI is feasible to assess tumor extent and multifocality in invasive breast cancer patients.
However, CAD is not effective in evaluation of nodal status.
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Precise information regarding tumor extent, lymph node
(LN) status, and multifocality is of great importance in
breast cancer treatment and prognosis, as well as, recur-
rence prediction. In particular, negative margins in
breast-conserving therapy significantly affect local tumor
recurrence [1,2]. Axillary LN status is also a major prog-
nostic indicator and acts as a guide, in terms of the need
for adjuvant chemotherapy, in breast-cancer patients
[3]. Multimodal breast imaging techniques for the* Correspondence: seoboky@korea.ac.kr
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available, especially mammography (MMG), ultrasound
(US), computed tomography (CT), magnetic resonance
imaging (MRI), and 18-fludeoxyglucose positron emis-
sion tomography (FDG-PET). There are several studies
comparing the diagnostic performance of these modal-
ities, with breast MRI reported to be the most accurate
imaging modality for assessment of tumor extent and LN
status [4-7].
Breast MRI, however, has various specificity, and high
false positive rates, when detecting breast cancers and
also tends to overestimate tumor extent [8-11]. Thus,
physicians have not achieved a consensus on the
utilization of MRI staging prior to surgery. Evaluation of
breast cancer using MRI takes significant time for imagehis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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and intra-observer variations are an additional drawback
of breast MRI [14].
Various commercially available computer-aided detec-
tion (CAD) systems for breast MRI have been intro-
duced to address these limitations. CAD automates and
speeds up image processing and analysis functions [10],
and detects breast lesions by using an enhancement
threshold. The system provides both morphologic and
kinetic features of the breast lesion, and also provides
quantitative information, such as, lesion dimensions and
maximum tumor volumes. Levrini et al. [15] reported
that CAD is just as accurate as breast MRI for size as-
sessment of breast lesions. In addition, Bhooshan et al.
[6] demonstrated that CAD for MRI could differentiate
between invasive and noninvasive breast lesions, and
also, between invasive breast cancers with LN metastasis
and invasive cancers without LN metastasis. There are
few clinical reports, however, showing the utility of CAD
for MRI in tumor staging [6,15].
The purpose of this preliminary study was to com-
pare diagnostic accuracy for preoperative assessment
of tumor extent, LN status, and multifocality in inva-
sive breast cancers among multimodal breast imaging
options, such as, MMG, US, CT, MRI, and FDG-PET. In
addition, our specific goal was to investigate if CAD for
MRI can be extended from cancer detection to cancer




Institutional review board approval was obtained from
the Korea University Ansan Hospital, and the require-
ment for informed consent was waived for this retro-
spective review. We searched our institution’s database
for invasive breast cancer patients who underwent all
imaging modalities from August 2008 to February 2012,
including MMG, US, CT, MRI with CAD, and FDG-PET
before breast cancer surgery. Of 211 invasive breast can-
cer patients, 147 patients, who underwent all imaging
modalities, were initially included. Among these 147 pa-
tients, we excluded 34 patients who underwent neo-
adjuvant chemotherapy, or excisional biopsy, within
6 months because recent neoadjuvant chemotherapy, or
excisional biopsy, may produce complications or changes
in surrounding breast tissues, which could interfere with
the pathologic-radiologic correlation. Further, of the 34 ex-
clusions, twenty patients of the patients had no surgical
confirmation, and seven patients did not receive sentinel
LN biopsy or axillary LN dissection. Four patients who
had no detectable lesions on CAD were included in
our study to reflect possible false negative results of
CAD. Therefore, a total of 86 patients (mean ages: 49.18,range: 28–82 years old) were included in this study. Patho-
logical diagnoses of these patients included 77 invasive
ductal carcinomas, four invasive micropapillary carcin-
omas, one invasive lobular carcinoma, one invasive apo-
crine carcinoma, one invasive mucinous carcinoma, one
invasive cribriform carcinoma, and one adenoid cystic car-
cinoma. Forty-five patients underwent modified radical
mastectomy, and the remaining 41 patients underwent
breast conserving surgery. All patients underwent senti-
nel LN biopsy, and 56 patients underwent axillary LN
dissection.
Imaging techniques
All 86 patients underwent multimodal breast imaging
using a digital MMG unit (Selenia FFDM system, Holo-
gic Cooperation, Denver, CO, USA), US units (LOGIQ 9
unit, GE Medical Systems, Milwaukee, Wis, USA and
iU22, Philips Medical Systems, Bothell, WA, USA), a
64-channel multidetector CT scanner (Brilliance 64-
channel, Philips Medical Systems, Cleveland, OH, USA),
a 3 T MRI system (Achieva 3.0 T TX, Philips Medical
Systems, Best, the Netherlands), and a PET/CT scanner
(Gemini TF/Brilliance 16, Philips Medical Systems, Best,
the Netherlands).
MMG captured both craniocaudal and mediolateral
oblique views. US examination was performed in bilat-
eral whole breasts, and axillae, with high-frequency lin-
ear transducers, also, survey scanning was performed in
transverse and sagittal planes. CT examinations were
performed by dynamic study after intravenous infusion
of 130 ml of nonionic contrast media (Iopamiro 300,
Bracco, Italy or Ultravist, Schering, Germany) at a rate
of 2.0 ml/sec. Early phase post-contrast images were ob-
tained 90 seconds after contrast media injection, and de-
layed phase post-contrast images at 300 seconds after
injection. The CT scan was performed at a low-dose set-
ting (120 kVp and 30 or 50 mAs).
For MRI, we obtained axial T2-weighted turbo spin
echo images, dynamic sagittal T1-weighted gradient
echo images with fat saturation, and axial and coronal
3D reconstruction images with maximum intensity pro-
jection. T2-weighted scan was performed; TE/TR 120/
9022 ms, inversion delay spectral attenuated inversion re-
covery (SPAIR), 125 ms, flip angle 90°, field of view (FOV)
340 × 340 mm2, acquired voxel size 1.01 × 1.31 × 2.0 mm3,
reconstructed voxel size 0.66 × 0.66 × 2.00 mm3. Fat-
saturated T1-weighted images were acquired before
and after contrast media injection with a total of six dy-
namic acquisitions; TE/TR 1.3/3.4 ms, flip angle 10°,
FOV 320 × 320 mm2, acquired voxel size 0.91 × 0.91 ×
2.00 mm3, reconstructed voxel size 0.83 × 0.83 × 1.00 mm3.
Twenty ml of 0.5 mmol/ml Gadodiamide (Omniscan,
Nycomed-Amersham, Princeton, NJ, USA) was injected
intravenously followed by a 20-ml saline flush at the rate of
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commercially available CAD system (CADstream software,
version 5.2.8.591, Merge Healthcare, Chicago, IL, USA).
For FDG-PET scan, CT images were obtained after
FDG injection and then PET scans were performed. PET
acquisition data were reconstructed using the 3D row
action maximum likelihood algorithm. Reconstruction
was performed to yield slices containing 144 × 144 pixels.
We obtained 3D maximum intensity projection images,
axial images with a slice thickness of 4 mm, and coronal
and sagittal images with a slice thickness of 4.6 mm.
Image evaluation
Two radiologists with 3 or 13 years of experience in
breast imaging interpreted all images using a picture ar-
chiving and communication system (PACS). One radi-
ologist had 3 years of experience in CAD reading and
the other had 5 years of experience. The radiologists
used consensus double reading. Each reader independ-
ently evaluated images and the final decision was
reached by discussion between the two readers. US im-
ages and mammograms were reviewed at the time of
CT, MRI, or FDG-PET interpretation. The radiologists
were blinded to the final pathological results. The Breast
Imaging Reporting and Data System (BI-RADS) lexicon
was used for diagnosis of malignant tumor on MMG,
US, and MRI [16]. Morphology on MMG, US, and MRI,
and kinetic features on MRI were evaluated. On breast
CT, focally-enhancing lesions, after contrast injection,
were evaluated [17]. On PET/CT, breast lesions were
suspected to be malignant if they showed elevated tracer
uptake when compared with the adjacent breast tissue.
For tumor extent, the longest diameter of a breast
tumor was recorded using each modality (Figure 1). On
MMG, tumor sizes were measured with both craniocau-
dal and mediolateral oblique views, and then the max-
imum length was chosen. Tumor sizes were measured
on multi-sections using US, CT, FDG-PET, and MRI,
and then the longest length was selected. CAD system
automatically provided maximum tumor extent if we
clicked the enhancing tumor.
A lymph node was considered as metastasis if it had
more than one of these characteristics: 1) the longitudinal-
transverse axis ratio of the LN was less than two; 2) the
cortex of the LN was concentrically or eccentrically thick-
ened more than 3 mm; 3) fatty hilum was absent or dis-
placed; 4) there was extranodal fat infiltration; 5) the LN
showed early enhancement with a delayed washout pat-
tern on dynamic CT and MRI; or 6) the LN showed in-
creased standardized uptake value (SUV) on FDG-PET. If
the axillary LN exhibited any of the findings mentioned
above, it was defined as metastatic LN. LNs that exhibited
none of the above mentioned criterion were defined as
negative for axillary LN metastasis [18,19]. On MRI, weused fat-saturated T1-weighted imaging for assessment of
LN status, and we often used precontrastT2-weighted im-
ages for evaluation of extranodal fat infiltration. We also
evaluated presence of multifocality of breast carcinomas
on all imaging modalities.
For CAD analysis, a color overlay map was placed on
all enhancing lesions at a 50% enhancement threshold
level in a pixel by pixel comparison across a pre-
contrast, early post-contrast, and delayed post-contrast
series, and set threshold of 50% could not be altered
during the analysis of individual lesions. Numerous prior
studies have used higher enhancement thresholds, more
than 50%, to improve specificity [13,20,21]. Levman
et al. [22]. insisted that enhancement thresholds can
limit a CAD test’s ability to diagnose a lesion’s full size
and, as such, should not be raised above 60%. However,
the signal enhancement ratio (SER) method exhibits a
high rate of false positives at low enhancement thresh-
olds. Therefore, they demonstrated that the most appro-
priate threshold would be 50%–60%. Based on these
previous studies, we selected a 50% threshold in this
study.
The initial phase determined by the signal change be-
tween the pre-contrast and early, post-contrast, series
was classified as medium (50–100%), or rapid (>100%)
enhancement. Delayed-phase enhancement type, after
early post-contrast series, was classified as persistent,
plateau, or washout. The washout type, displayed in red,
represented pixel signal intensity with at least a 10% de-
crease in the delayed post-contrast series compared to
the early post-contrast series. The persistent type, dis-
played in blue, represented pixel signal intensity with at
least a 10% increase in the delayed post-contrast series
compared to the early post-contrast series. The plateau
type, displayed in green, represented pixel signal inten-
sity with a less than 10% increase, and a less than 10%
decrease, compared to the early post-contrast series.
Morphologic evaluation was also performed based on
the BI-RADS lexicon [16]. Although a lesion had mor-
phologically non-malignant features, such as, a circum-
scribed margin and oval shape, we considered it as
malignant if the lesion had malignant kinetic features or
strong enhancement about the threshold on CAD. For
measurement of tumor extent with CAD, an enhancing
tumor above the threshold was selected with the color
overlay map, and then the, CAD-generated, maximum
tumor size was recorded. For evaluation of nodal status
on CAD, LNs above threshold enhancement were indi-
vidually selected by radiologists and the presence of sig-
nificant enhancement, as indicated by the presence of a
color overlay map on the LN, was recorded as positive
LN. These findings were confirmed using same-level
breast MRI images because CAD sometimes detected
engorged axilla vessels as positive LN. We determined
Figure 1 How to measure the tumor extent. The longest diameter
of a breast tumor was recorded using each modality; MMG (A), US (B),
CT (C), MRI without CAD (D), MRI with CAD (E), and FDG-PET (F). For
measurement of tumor extent with CAD, an enhancing tumor above
the threshold was selected with the color overlay map, and then
CAD-generated maximum tumor size was recorded.
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etic features on CAD.
Pathological examination
Pathologic specimens were obtained within 2 weeks after
the acquisition of preoperative images. Specimens were
prepared by making serial 5-mm slices of breast-
conserving surgical specimens, and 5–10-mm slices of
mastectomy specimens, according to the technique re-
ported by Egan [23]. For the correlation of pathological
findings and breast imaging features, pathologists and
radiologists reviewed all specimens together. For assess-
ment of LN status, sentinel lymph node biopsy was per-
formed and then evaluated with frozen microscopic
examinations. If there was a positive sentinel lymph
node, axillary node dissection was performed. For diag-
nosis of multifocality, an imaging-guided core biopsy,
prior to surgery, or a needle-localization and excisional
biopsy, during surgery, was performed on suspicious
additional breast lesions. Pathologists reviewed all patho-
logic findings and reported tumor extent, nodal status,
and multifocality of invasive breast carcinomas.
Analysis
Evaluated tumor extent, LN status, and multifocality of
invasive breast carcinomas on breast-imaging modalities
were compared with actual pathological results. For as-
sessment of the accuracy of tumor extent on each mo-
dality, correlation coefficients were calculated using the
Spearman rank correlation test in order to assess the
strength of the linear association between the pathologic
tumor size, and the recorded size, from each modality.
The pathologic tumor size was considered to be the
tumor extent on pathological examination. The Mann–
Whitney test was used to investigate whether there were
size differences between the pathologic tumor size and
the recorded size on each imaging modality. Further, the
Kruskal-Wallis test was used to study whether there
were significant differences between various imaging
modalities for the assessment of tumor extent.
Weighted kappa coefficients were used to find the
agreement of LN status between multimodal breast im-
aging and actual pathological results. A kappa coefficient
greater than 0.80 indicated excellent agreement, 0.61-
0.80 good agreement, 0.41-0.60 moderate agreement,
0.21-0.40 fair agreement, and less than 0.20 poor
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pare the LN status on multimodality breast imaging and
final pathological results. Sensitivity, specificity, positive
predictive value (PPV), and negative predictive value
(NPV) were calculated.
For comparison of the accuracies of diagnosis of mul-
tifocality on the various imaging modalities, standard
receiver operating characteristic analysis was used to
generate sensitivity, specificity, and area, under the
ROC curve (AUC) of imaging modalities used for de-
tecting multifocality in a breast cancer patients. AUC
equal to 1 indicated a perfect test, 0.7-0.9 moderate
accuracy, 0.5-0.7 less accuracy, and equal to 0.5 was
non-informative. Statistical analyses were performed using
SAS version 9.1 (SAS Institute, Cary, NC, USA). P values




Table 1 demonstrates lesion characteristics of all 82
invasive carcinomas with measured tumor extent on
multimodal breast imaging including CAD. Mean and
median values of tumor extent, and correlation coeffi-
cients between pathologic tumor size and recorded size
on multimodal breast imaging, are shown on Table 2.
The median pathological tumor extent was 22 mm.
All imaging modalities yielded statistically significant
measurements with a range of correlation coefficients,
0.513-0.766 (P < 0.05). The correlation coefficient was
highest in MRI without CAD, followed by CT, US,
MMG, FDG-PET, and MRI with CAD. The Kruskal-
Wallis test was used to investigate whether there were
statistically significant size differences between all imagingTable 1 Lesion characteristics of 86 invasive breast
carcinomas using multimodal breast imaging
Imaging modality Lesion characteristics
Mammography Mass 29 (33.6%)
Calcifications 3 (3.5%)
Mass with calcifications 36 (41.9%)
Asymmetry 18 (21.0%)
Ultrasound Mass 46 (53.5%)
Mass with calcifications 32 (37.2%)
Mass with abnormal ducts 8 (9.7%)
CT Enhancing mass 86 (100.0%)
MRI Mass 76 (88.4%)
Non-mass-like enhancement 10 (11.6%)
FDG-PET Elevated tracer uptake with enhancing
mass 86 (100.0%)
CT computed tomography, MRI magnetic resonance imaging, FDG-PET
18-fludeoxyglucose positron emission tomography.modalities, and the result indicated there were no sig-
nificant size differences between the six imaging types
(P = 0.165). In addition, the Mann–Whitney test was
used to investigate if there were differences between
pathologic tumor size and recorded tumor size. There
were no significant differences between pathologic tumor
size and recorded size on US, CT, or MRI with or with-
out CAD (P > 0.05), but there was a significant size differ-
ence between pathologic tumor size and recorded size on
FDG-PET (P = 0.007).
LN status
Table 3 demonstrates weighted kappa coefficients for
agreement of LN status between multimodality breast
imaging and actual pathological results. The coefficients
ranged from 0.158 to 0.420. US and CT had moderate
agreement. MMG, MRI without CAD, and FDG-PET
had fair agreement. CAD for MRI showed the worst re-
sult; poor agreement.
Table 4 shows diagnostic performance of LN status
with multimodal breast imaging assessed using the Chi-
square test. All imaging modalities had higher values of
specificity and PPV than those of sensitivity and NPV.
US was the best imaging modality, with higher values of
sensitivity (61.4%), specificity (92.1%), PPV (90.0%), and
NPV (67.3%). MMG and FDG-PET had high values of
specificity (86.8%, 81.6% respectively) and PPV (76.2%,
75.0%), however, sensitivity (36.4%, 47.7%) and NPV
(54.1%, 57.4%) were very low. CT and MRI without CAD
had a range of 61.4%-78.9% in all diagnostic perform-
ance parameters. CAD for MRI did not improve diag-
nostic performance when compared with MRI without
CAD.
Multifocality
Six of the total 86 patients had multiple carcinomas on
pathologic examination. The number of multifocal le-
sions for each patient ranged from two to four. Five of
these six (83.3%) patients underwent mastectomy and
only one patient underwent breast conserving surgery.
The surgical plan was changed in three (50%) patients
due to multifocality. Table 5 and Figure 2 present the
sensitivity, specificity and AUC of each imaging modality
for detecting multifocality in breast cancer patients.
Sensitivity was the best in MRI with or without CAD
(100%, 6/6) compared with other imaging modalities.
FDG-PET had the highest value of specificity (93.4%,
71/76), however, it had the lowest value of sensitivity
(33.3%, 2/6). AUC ranged from 0.634 to 0.888. MRI with
CAD had the highest AUC value. All imaging modalities
except FDG-PET yielded statistically significant AUC and
were moderately accurate (0.7 < AUC < 0.9) at detecting
multifocality. Sensitivities of MRI with or without CAD
for detecting multifocality of breast cancer were 100%.
Table 2 Tumor size and correlation coefficients representing the strength of a linear association between pathological
tumor sizes and recorded sizes with multimodal breast imaging
Pathology Mammography Ultrasound CT MRI without CAD system MRI with CAD system FDG-PET
Mean tumor size 25.2 ± 14.8 30.7 ± 19.1 28.5 ± 17.7 27.6 ± 15.6 29.1 ± 16.3 28.3 ± 23.1 32.7 ± 21.5
Median tumor size 22 27 23 22 24 22 28
Size Range (3–74) (9–120) (5–100) (8–79) (8–78) (0.5-100) (0–103)
Correlation coefficients 0.583 0.656 0.711 0.766 0.513 0.616
CT computed tomography, MRI magnetic resonance imaging, CAD computer-aided detection system, FDG-PET 18-fludeoxyglucose positron emission tomography.
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compared with that of MRI without CAD (61.8%).
Discussion
Breast cancers are dependent on angiogenesis for growth
and development, because they need blood vessels to ob-
tain nutrients [25]. Dynamic breast MRI is sensitive to
variations in vascular permeability and blood volume,
which can be associated with tumor angiogenesis [26].
Signal enhancement ratio, a quantitative method for
characterizing angiogenesis in breast cancer, measures
changes in contrast signal intensity over three time
points and acts as a surrogate marker for contrast kinet-
ics [27]. CAD uses the SER to compute the angiomap
which refers to an image with color-coded tumors repre-
senting kinetic information and provide volume, max-
imal intensity projection, multi-planar reform, and the
curve classification of enhancing lesions. As suggested
by Hylton [25], SER can provide signs that correlate with
angiogenesis. In detail, CAD incorporates unenhanced
images and contrast-enhanced images and then com-
pares pixel signal intensity values on the immediate- and
delayed-contrast enhanced images to indicate washout,
plateau, or persistent enhancement pattern based on
pixel value increases above a user-specified minimum
enhancement threshold [28]. Specific colors such as
blue, green and red are assigned to each pixel for differ-
ent types of tissue enhancement, such as persistent,
plateau and washout, respectively [28]. CAD is a post-
processing software program that performs image ana-
lysis and integrates with MRI automatically. Its abilities
to promptly analyze considerable numbers of images,
facilitate reconstructions, aid in visual subtraction,
and increase tumor detection rates are considerable ad-
vantages. CAD also improves the interpretation efficiency
and diagnostic performance of radiologists by reducingTable 3 Weighted kappa coefficients for agreement of LN sta
pathological results
Mammography Ultrasound CT
Weighted kappa coefficients 0.223 0.522 0.420
CT computed tomography, MRI magnetic resonance imaging, CAD computer-aidedreading time and maintaining the consistency of lesion
detection [12].
CAD for MRI has been developed for breast cancer
detection. Although the system provides automatic size
and volume data and regional LN information, up to
now there have been few reports that have demonstrated
the utility of CAD for preoperative tumor staging [6,15].
In this study, we investigated the feasibility of CAD for
assessment of tumor extent, LN status, and multifocality
in invasive breast cancers by comparing CAD for MRI
with other breast imaging modalities, including MMG,
US, CT, MRI without CAD, and FDG-PET.
In terms of tumor extent, all imaging modalities
tended to overestimate tumor size compared with actual
pathological size, but there was no significant difference
between recorded size and pathological size, except with
FDG-PET. Small underestimation of actual pathological
size can be explained by shrinkage of tissues during fix-
ation and processing [29]. On FDG-PET, breast cancers
with higher SUV can be overestimated due to the over-
flow effect and small cancers with lower SUV can be
underestimated due to the partial volume effect. In
addition, size measurement is affected by manipulation
of scale bar. Uematsu et al. [7] and Heusner et al. [30]
also reported that FDG-PET has significantly lower ac-
curacy than MRI for measurement of tumor extent and,
thus, is not to be recommended for this purpose. In our
study, manual measurement on MRI was the best mo-
dality to assess tumor extent. US, CT, and MRI were
more accurate than mammography, and thus, good im-
aging types to assess breast cancer staging. Although the
correlation coefficient of MRI without CAD was higher
than that of MRI with CAD, there was no statistically
significant difference between automatically measured
tumor size on CAD and manually measured tumor size
on MRI in this study. However, a preliminary study bytus between multimodality breast imaging and
MRI without CAD system MRI with CAD system FDG-PET
0.346 0.158 0.285
detection system, FDG-PET 18-fludeoxyglucose positron emission tomography.
Table 4 Diagnostic performance of the determination of LN status with multimodality breast imaging
Mammography Ultrasound CT MRI without CAD system MRI with CAD system FDG-PET
Sensitivity (%) 36.4 61.4 63.6 61.4 47.7 47.7
Specificity (%) 86.8 92.1 78.9 73.7 68.4 81.6
PPV (%) 76.2 90.0 77.8 73.0 63.6 75.0
NPV (%) 54.1 67.3 65.2 62.2 53.1 57.4
CT computed tomography, MRI magnetic resonance imaging, CAD computer-aided detection system, FDG-PET 18-fludeoxyglucose positron emission tomography,
PPV positive predictive value, NPV negative predictive value.
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CAD tumor sizes are less accurate in predicting the size
of residual malignancy than those measured by the radi-
ologist. Therefore, further study in a large population
would be necessary to evaluate utility of automatic
tumor measurement of CAD.
In terms of LN status, MMG, US, CT, MRI, and FDG-
PET all had fair-to-moderate agreement between breast
imaging and actual pathological results, and all imaging
modalities showed higher specificity values than sensitiv-
ity values in detecting metastatic LN. US demonstrated
the best diagnostic performance in evaluating LN status,
a finding that has been reported in previous studies
[32-34]. Sensitivity and NPV were not satisfactory, how-
ever, despite US having the best results. Alvarez et al.
[34] reported axillary US was moderately sensitive and
quite specific in the diagnosis of axillary LN metastasis,
and thus negative sonographic results do not exclude
the presence of metastasis. US-guided biopsy, or aspir-
ation of sonographically suspicious nodes, would be rec-
ommended to increase the specificity.
To our knowledge, the use of MRI with CAD for LN
evaluation has not been reported. In this study, CAD
showed limitations in identifying LN metastasis in inva-
sive breast cancers. CAD had the worst correlation coef-
ficient for agreement of determined LN status with
pathological results among the breast imaging modalities
studied. CAD also did not improve diagnostic perform-
ance values of breast MRI when compared with MRI
alone in the evaluation of LN status. Therefore, CAD is
useful in evaluating the breast itself, but may be limited
in assessing LN status in breast cancer patients.
In terms of the detection of multifocality in invasive
breast cancers, MMG, US, CT, and MRI had satisfactoryTable 5 Overall sensitivity, specificity, and AUC for evaluation
Mammography Ultrasound CT M
Sensitivity (%) 66.7 83.3 66.7 1
Specificity (%) 89.5 71.1 79.0 6
AUC 0.781 0.772 0.728 0
P value 0.00 0.00 0.03 0
CT computed tomography, MRI magnetic resonance imaging, CAD computer-aided
PPV positive predictive value, NPV negative predictive value, AUC area under the ROresults. FDG-PET had very low sensitivity (33.33%) even
though it had high specificity (93.42%), and thus had an
AUC value that was significantly lower than the other
imaging modalities. Breast MRI had higher sensitivity
(100%) and higher AUC value (0.809) than MMG, US,
CT, or FDG-PET. CAD improved the specificity (77.63%)
of breast MRI for detection of multiple breast cancers with
preservation of the sensitivity of MRI, and thus had the
best AUC value (0.888).
CAD for MRI has a number of advantages in detecting
breast cancers. The system handles large images with
speed and provides an angiomap and colored imaging
that can correlate with kinetic features of a breast lesion.
This enables easy detection of abnormal breast lesions.
CAD also can improve lesion contrast and diagnostic
performance, especially specificity [12]. These advan-
tages may improve the ability to detect multifocality
on MRI. Detection of mulfocality is essential to plan
surgical methods and to reduce tumor recurrence. In
this study, three patients who had multifocal cancers
changed their surgical planning form conservation to
mastectomy.
Although our preliminary results are promising, there
were several limitations to the study. First, it is a retro-
spective review of nonconsecutive patients with invasive
breast cancers. Second, the number of patients was
small. Furthermore, we did not evaluate differences in
the measurement of tumor extent or multifocality ac-
cording to the tumor morphology on breast imaging.
For example, mass or non-mass like enhancement on
MRI may produce different results. Further validation
using a larger study population is warranted. Third,
tumor extents in each modality were not measured in
the same orientation- e.g. we recorded tumor extent onof multifocality with multimodality breast imaging





detection system, FDG-PET 18-fludeoxyglucose positron emission tomography,
C curve.
Figure 2 Summary of ROC curve of each imaging modality for detecting multifocality in breast cancer patients. AUC was 0.781 for MMG,
0.772 for US, 0.728 for CT, 0.809 for MRI without CAD, 0.888 for MRI with CAD and 0.634 for FDG-PET.
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on MRI in axial or sagittal orientation, on US in any
orientation. Size measurement in these various orienta-
tions may affect the results, although we measured
tumor extent in multiple planes and then recorded the
longest diameter of a breast tumor in each modality.
Fourth, the patients’ order was randomized. but the im-
ages were not presented to the radiologists in a random-
ized order. The radiologists independently evaluated a
series of images from each patient, similar to the real
clinical practice. However, this may produce a bias of
image interpretation. It is recommended that a clinical
study in a large population, utilize completely random-
ized image order to assess CAD utility. Fifth, we did not
perform node-to-node correlation, but rather, case-to-
case correlation with imaging and pathological results.
Sixth, various CAD systems are customized for various
kinds of MRI. Therefore, it is not certain that our results
will be precisely reproducible if we use another kind of
CAD or MRI. Finally, MR images were assessed in the
light of mammographic or US findings.
Conclusions
In conclusion, CAD for breast MRI can be a feasible
method of evaluating tumor extent and multifocality in
invasive breast cancer patients. Although manual meas-
urement of tumor extent on MRI had a higher correlation
coefficient with pathologic size than automatized meas-
urement of CAD, there was no statistically significantdifference. Detection of multifocality is important for sur-
gical planning and prevention of residual tumors or recur-
rence. However, CAD is limited in evaluating LN status.
US is the most accurate diagnostic tool for axillary LN
metastasis and can help to overcome the limitations of
CAD for MRI. Based on our preliminary results, utility of
CAD may be extended from cancer detection to cancer
staging, with particular regard to tumor extent and multi-
focality, for determination of treatment and prognosis in
clinical settings.
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